Markets:

Overview

News

Currencies

International

Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

Motley Fool Co-Founder David Gardner Reviews Stock Picks ↗

July 11, 2025

Via The Motley Fool

Exploring bluebird bio's Earnings Expectations ↗

November 13, 2024

Via Benzinga

Which stocks are moving on Wednesday? ↗

May 14, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session. ↗

May 14, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity ↗

May 14, 2025

Bluebird Bio revised its agreement with Carlyle and SK Capital, adding a $5 per share cash option for stockholders ahead of deal completion.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 14, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 14, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Top stock movements in today's session. ↗

March 31, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

BlueBird Shares Are Up Today: What's Going On? ↗

March 31, 2025

Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.

Via Benzinga

Monday's session: top gainers and losers ↗

March 31, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 31, 2025

Via Benzinga

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps ↗

March 31, 2025

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 28, 2025

Via Benzinga

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal ↗

March 11, 2025

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session. ↗

February 21, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Dow Tumbles Over 700 Points; US Services PMI Falls In February ↗

February 21, 2025

Via Benzinga

Topics Stocks

Top movers in Friday's session ↗

February 21, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Stocks Firmly Lower As Consumer Sentiment Weakens ↗

February 21, 2025

The Dow Jones Industrial Average is headed for another sharp triple-digit drop to end the week.

Via Talk Markets

Topics Stocks Stocks / Equities

Gapping stocks in Friday's session ↗

February 21, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 21, 2025

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

What's Going On With Gene Therapy Company Bluebird Bio Stock Today? ↗

February 21, 2025

bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 05, 2024

Via Benzinga

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

December 05, 2024

Via Benzinga

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program ↗

December 04, 2024

CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.

Via Benzinga

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy ↗

November 29, 2024

The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies.

Via Benzinga

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options ↗

November 15, 2024

Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.

Via Benzinga

Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy ↗

October 11, 2024

A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have...

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.